Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764618 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
A Phase 3 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT03764618 is a Phase 3 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT03764618, a Phase 3 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Interventions
- DRUG Placebo
- DRUG Fostamatinib disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764618
The ClinicalTrials.gov registry entry for NCT03764618 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03764618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03764618 about?
NCT03764618 is a clinical study titled "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA". The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
What is the current status of trial NCT03764618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2019-04-24. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT03764618?
The interventions under investigation include: Placebo (DRUG), Fostamatinib disodium (DRUG).
Who is sponsoring clinical trial NCT03764618?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.